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he Institute for Advancing Medical Innovations (IAMI) was founded in 
January 2009 with an $8.1 million funding from the Kauffman foundation and 
a matching contribution from the University of Kansas Endowment 
Association. The $16.2 million funding for five years was targeted to: 1) advance novel, 
new medical innovations for the diagnosis, treatment, prevention and control of 
human and animal disease to clinical proof of concept, 2) create a culture of multi-
disciplinary, multi-organizational collaboration, and 3) prepare graduate and 
postdoctoral student for careers in development and commercialization of medical 
innovations. A staff of experienced project managers and management with over 100 
years of pharmaceutical industry experience, and an external advisory board of 
experienced entrepreneurs and an adjunct faculty to mentor graduate fellows supports 
IAMI. Annual investment of $1.6 million is for proof-of concept (POC) projects 
initiated by KU faculty both at the Lawrence campus and the medical center in Kansas 
City. This investment is intended as a key differentiator for the National Cancer 
Institute (NCI) designation for the University of Kansas Cancer Center and the Clinical 
Translational Science Award currently under preparation.  
  
Introduction 
Academic research in science and 
technology has been one of the main 
drivers in economic development, 
prosperity and dramatic improvement in 
public health in the developed countries. 
This is particularly evident in the 20th 
century United States with the discovery 
of the transistors, microelectronics, 
microcomputers and the Internet in the 
telecommunications arena. In health 
sciences, the development of polio 
vaccine, antibiotics, and the advent of 
molecular biology, DNA structure, 
human genome and innovations in 
medical devices have revolutionized 
public health. Much of this discovery 
and development effort has strong roots 
in the basic science and technology 
research actively supported by the 
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government and the universities. For 
example, the development of the Silicon 
Valley and the biotech industries in 
California, Massachusetts, Washington, 
North Carolina and other states, are 
located around strong academic 
communities that promote venture 
capital and start up companies that have 
flourished since the 1950s.  
The Institute for Advancing Medical 
Innovations (IAMI) currently in place at 
the University of Kansas (KU) is a bold 
step in this direction to promote 
translational research by the faculty and 
students which will contribute strongly 
to the economic development in Kansas 
and the Kansas City region. We 
anticipate that this effort in partnership 
with the Kauffman Foundation, Kansas 
Biosciences Authority (KBA) and 
regional animal and bioscience industry 
will promote entrepreneurship and 
economic development. 
As shown in Figure 1, IAMI 
supports Proof-of-Concept (POC) 
projects in drug discovery and delivery 
along with innovative approaches to 
drug-device development that can lead 
to commercialization through start up 
companies based on research funded at 
KU. Partnerships will be entertained and 
encouraged with national and 
international universities, companies 
and philanthropic organizations to 
deliver life-saving products to patients. 
Revenues from these activities will be 
used to fund translational research at 
KU and in the Kansas City region. As 
part of this effort, IAMI will provide 
training and mentoring for faculty and 
students on entrepreneurship, business 
development, intellectual property 
management and venture funding in 
collaboration with the KU Business 
School and the University of Kansas 
Center for Technology 
Commercialization (KUCTC).  
Proof-of-Concept Projects: 
IAMI and the Kauffmann 
foundation, the largest non-profit 
organization that supports 
entrepreneurship, intended that the 
Figure 1: Functional architecture of IAMI
  56 
funds would leverage translational 
projects derived from federal research 
dollars to KU. The annual $16 million 
funding will be for five years to support 
POC projects.  
Figure 2 illustrates an idea that 
starts on pieces of paper and a test tube 
on the basis of basic science research 
supported by federal and philanthropic 
research grants. Scientists drive these 
ideas and projects through various 
stages of early development that mostly 
result in significant scientific 
publications and serve to train students 
and post-doctoral scientists. Many of the 
discoveries, when carefully evaluated, 
may have benefit for patients and the 
public and require rigorous research 
development activities before 
commercialization. Work needs to be 
done in in-vivo animal studies and then 
in expensive human clinical trials with 
appropriate product type (formulation, 
device etc.) to advance discoveries to the 
patients and the public. 
 In the past, this aspect of 
translational research is generally not 
funded by federal agencies or 
philanthropic research organizations, 
but carried out by multinational 
corporations and biotechnology 
companies based on academic 
publications. Lack of such support 
resulted in lost economic opportunities 
for the universities, academic 
researchers and the region- generally 
identified as the “Valley of Death” for 
the projects that have commercial 
potential. The projects at this stage are 
too early for venture capital investment 
and too advanced for basic research 
funding. IAMI targets the translational 
research activities with specific 
milestone-based funding and project 
management support from industry 
experienced project managers and 
adjunct faculty.  
Note that prior to the establishment 
of IAMI, the Office of Therapeutics and 
Drug Development (OTDD) lead by Dr. 
Scott Weir promoted three projects that 
are in the clinic as shown in Figure 2. 
Nanotax® is nano-crystalline form of 
Paclitaxel for ovarian cancer that is 
currently in Phase I at the University of 
Kansas Cancer Center, and was a KU 
innovation to minimize side effects in 
the current marketed formulation. The 
Ciclopirox Olamine is a project to 
support a blood cancer therapy with the 
Figure 2: The Discovery and Development Pyramid
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National Leukemia Lymphoma Society 
and the University of Toronto, Princess 
Margaret hospital, while SR-13668 is a 
collaborative project with the Mayo 
Clinic for cancer prevention. We have 
several other projects with Children’s 
Mercy Hospital in Kansas City and the 
Institute of Pediatric Innovation in 
Boston, on translational projects 
bringing innovative drugs and 
formulations for pediatric patients. 
The requirements for selecting POC 
projects are shown in Table 1. Once the 
request for proposals (RFP) are 
announced within KU, principal 
investigators and students submit a 
letter of intent (LOI) to IAMI and meet 
with project managers to plan the 
preparation of the grant proposals. Note 
that the criteria described in the Table 
below strongly encourage applicants to 
submit relevant information on their 
science, technology, intellectual property 
and commercialization potential. These 
proposals are, therefore, quite different 
from other basic science grant 
applications. Both the faculty and 
students learn many aspects of 
innovation and commercialization that 
are not part of normal university 
curriculum. 
• Medical innovation novelty (unmet need) 
• Potential market size 
• Market definition 
• Medical innovation maturity 
• Utility of proof of concept funding 
• Intellectual property position 
• Principal investigator credibility 
Table 1: POC Criteria: Project objectives, go/no go 
decision points, and detailed project plans are 
required for funding consideration. 
The full applications are reviewed 
by the IAMI advisory board that consists 
of nationally and internationally 
recognized leaders in translational 
pharmaceutical research, device 
development and venture investments 
in start up companies (Table 2). Since 
early 2009, twenty-five (25) POC projects 
have been funded at an investment 
commitment of $3.2 M to KU 
investigators in two review cycles. 
Christopher P. Austin, Director, National Institutes 
of Health Chemical Genomics Center 
Steven D. Averbuch, Vice President, Oncology 
Global Clinical Research, Bristol-Myers Squibb 
Company 
Michael D. Webb, Executive Chairman, Virtify, Inc. 
Anand C. Burman, Chairman of the Board, Dabur 
India Limited, New Delhi, India 
David Vranicar, President, Heartland Bioventures, 
Kansas Bioscience Authority 
David Jenkins, Managing Partner, FatBoy Capital, 
L.P. 
Thomas Wiggans, former Chief Executive Officer 
and Chairman of the Board, Peplin, Inc. 
Table 2: The IAMI advisory Board and their 
affiliations. All but Dr. Austin are KU alums with 
successful careers in biotechnology and medical 
device industries. 
IAMI Fellows Training Program 
As part of its commitment to the 
educational mission of the university 
and training entrepreneurs, IAMI 
funds fellowships for 10 graduate 
students and 4 post-doctoral scientists 
at KU on an yearly basis. One 
additional post-doctoral scientist is 
funded at the Kauffman National 
Fellowships program through IAMI. 
The Fellows come from business 
school, chemistry, biology, 
engineering and related programs at 
KU, and have projects that are 
innovative. They are required to 
attend regular group meetings, meet 
with assigned adjunct instructors as 
  58 
mentors (Table 3), and submit annual 
progress reports to the IAMI 
management and the advisory board. 
They are required to work with KU 
Business School to develop business 
plans and funding proposals for 
venture capital firms. This is a unique 
opportunity for the IAMI fellows to 
develop their science and technology 
and conceptualize their business 
plans. 
Mike Baltezor (Formerly Enturia Inc, a Cardinal 
Health company, Kansas City, KS.) 
Andrew Parkinson (Xenotech, Kansas City, 
KS) 
Tony Barnes (Rules Based Medic, Austin, TX) 
John Neet (J.M. Neet & Associates. Lawrence, 
KS. 
Mike Beckloff (Beckloff Associates, a Cardinal 
Health company, Kansas City KS.) 
Matt McClorey (Lawrence Regional 
Technology, Lawrence, KS.) 
Tom Engler (Eli Lilly & Co. Indianapolis, IN.) 
Ken Lynn (New Link Genetics, IA) 
Bo Fishback (Kauffman Foundation, Orbis 
Pharmaceuticals Inc., Kansas City KS.) 
Table 3: IAMI adjunct Instructors: experienced 
entrepreneurs from Kansas and around the 
country. 
The Ellis Family Seminar Series: 
Through a philanthropic 
contribution from a donor, the Ellis 
Family Symposium was inaugurated 
in 2010 at the KU Lawrence campus 
and the medical center campus in 
Kansas City. The seminars are open to 
the public and are intended to invite 
individuals from regional industry, 
universities, and research institutes to 
discuss innovation and 
commercialization concepts in their 
own experience. All fellows are 
required to attend the seminars and 
special engagements with the speakers 
are also scheduled before or after the 
seminars. These interactions are 
designed to encourage free flow of 
ideas and discussion between IAMI 
fellows and reputed entrepreneurs 
and business owners who are 
successful in their own right.  
Conclusions: 
Academic research supported by 
federal agencies such as the National 
Institutes of Health, National Science 
Foundation and philanthropic 
organizations have narrowly focused on 
basic and applied science and 
technology that results in publications 
and serves the educational missions of 
our universities. However, even after the 
Bayh-Dole act of 1980, there is very little 
funding or infrastructure that supports 
translational research and promotes 
entrepreneurship, commercialization 
and job creation. Traditionally, the 
discoveries from academia have been 
exploited by multinational corporations 
and biotech industries concentrated in a 
small number of regional centers. More 
and more local and state governments 
are recognizing job creation potential 
and its impact on economic 
development in their localities - IAMI is 
an example of this desire to exploit 
academic innovations.  
IAMI is an innovative idea to 
support faculty entrepreneurs and local 
and regional economy by leveraging 
industrial expertise to commercialize 
discoveries at KU. As shown in Figure 3, 
by encouraging partnerships between 
researchers at both campuses and 
providing project management 
expertise, process re-engineering and 
training, we are fostering a culture of 
collaboration and innovation. An 
ultimate challenge in creating such 
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models in the academic environment is 
its sustainability over the long term and 
its impact on the local and national 
economies.  
 
Figure 3: Transforming Federally Funded Research into medical innovations 
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